Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review

被引:7
|
作者
He, Weixiang [1 ]
Ding, Ting [2 ]
Niu, Zhiping [3 ]
Hao, Chunlin [1 ]
Li, Chengbin [1 ]
Xu, Zhicheng [1 ]
Jing, Yuming [1 ]
Qin, Weijun [1 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Urol, Xian, Peoples R China
[2] Fourth Mil Med Univ, Xijing Hosp, Dept Clin Lab Med, Xian, Shaanxi, Peoples R China
[3] Fudan Univ, Sch Publ Hlth, Dept Environm Hlth, Shanghai, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
基金
中国国家自然科学基金;
关键词
benign prostate hyperplasia; lower urinary tract symptoms; surgery; retreatment; reoperation; HOLMIUM LASER ENUCLEATION; TERM-FOLLOW-UP; RANDOMIZED CONTROLLED-TRIAL; STANDARD TRANSURETHRAL RESECTION; TITANYL-PHOSPHATE LASER; URINARY-TRACT SYMPTOMS; PHOTOSELECTIVE VAPORIZATION PROSTATECTOMY; BLADDER OUTLET OBSTRUCTION; TRANSVESICAL PROSTATECTOMY; PLASMAKINETIC ENUCLEATION;
D O I
10.3389/fendo.2023.1287212
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Surgical treatment is important for male lower urinary tract symptom (LUTS) management, but there are few reviews of the risks of reoperation.Objective To systematically evaluate the current evidence regarding the reoperation rates of surgical treatment for LUTS in accordance with current recommendations and guidelines.Evidence acquisition Eligible studies published up to July 2023, were searched for in the PubMed (R) (National Library of Medicine, Bethesda, MD, USA), Embase (R) (Elsevier, Amsterdam, the Netherlands), and Web of Science (TM) (Clarivate (TM), Philadelphia, PA, USA) databases. STATA (R) (StataCorp LP, College Station, TX, USA) software was used to conduct the meta-analysis. Random-effects models were used to calculate the pooled incidences (PIs) of reoperation and the 95% confidence intervals (CIs).Evidence synthesis A total of 119 studies with 130,106 patients were included. The reoperation rate of transurethral resection of the prostate (TURP) at 1, 2, 3, and 5 years was 4.0%, 5.0%, 6.0%, and 7.7%, respectively. The reoperation rate of plasma kinetic loop resection of the prostate (PKRP) at 1, 2, 3, and 5 years was 3.5%, 3.6%, 5.7%, and 6.6%, respectively. The reoperation rate of holmium laser enucleation of the prostate (HoLEP) at 1, 2, 3, and 5 years was 2.4%, 3.3%, 5.4%, and 6.6%, respectively. The reoperation rate of photoselective vaporization of the prostate (PVP) at 1, 2, 3, and 5 years was 3.3%, 4.1%, 6.7%, and 7.1%, respectively. The reoperation rate of surgery with AquaBeam (R) at 1, 2, 3, and 5 years was 2.6%, 3.1%, 3.0%, and 4.1%, respectively. The reoperation rate of prostatic artery embolization (PAE) at 1, 2, 3, and 5 years was 12.2%, 20.0%, 26.4%, and 23.8%, respectively. The reoperation rate of transurethral microwave thermotherapy (TUMT) at 1, 2, 3, and 5 years was 9.9%, 19.9%, 23.3%, and 31.2%, respectively. The reoperation rate of transurethral incision of the prostate (TUIP) at 5 years was 13.4%. The reoperation rate of open prostatectomy (OP) at 1 and 5 years was 1.3% and 4.4%, respectively. The reoperation rate of thulium laser enucleation of the prostate (ThuLEP) at 1, 2, and 5 years was 3.7%, 7.7%, and 8.4%, respectively.Conclusion Our results summarized the reoperation rates of 10 surgical procedures over follow-up durations of 1, 2, 3, and 5 years, which could provide reference for urologists and LUTS patients.Systematic review registration https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023445780.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Evaluation of the Cost-Effectiveness of Surgical Treatment Options for Benign Prostatic Hyperplasia
    Wymer, Kevin M.
    Narang, Gopal
    Slade, Austen
    Sharma, Vidit
    Thao, Viengneesee
    Borah, Bijan J.
    Rivera, Marcelino
    Cheney, Scott
    Humphreys, Mitchell R.
    UROLOGY, 2023, 171 : 96 - 102
  • [42] Treatment of benign prostatic hyperplasia
    Nunes, Ricardo Vita
    Manzano, Joao
    Truzzi, Jose Carlos
    Nardi, Aguinaldo
    Silvinato, Antonio
    Bernardo, Wanderley Marques
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (02): : 95 - 99
  • [43] Tamsulosin Versus Terazosin for Benign Prostatic Hyperplasia: A Systematic Review
    Dong, ZhiLong
    Wang, ZhiPing
    Yang, KeHu
    Liu, YaLi
    Gao, WenHui
    Chen, WenYuan
    SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE, 2009, 55 (04) : 129 - 136
  • [44] Sexual Side Effects of Medical and Surgical Benign Prostatic Hyperplasia Treatments
    Welliver, Charles
    Essa, Ahmed
    UROLOGIC CLINICS OF NORTH AMERICA, 2016, 43 (03) : 393 - +
  • [45] Sophisticated surgical management of distinctive patients with benign prostatic hyperplasia (BPH)
    Madersbacher, S.
    Oelke, M.
    Haecker, A.
    Bschleipfer, T.
    UROLOGE, 2020, 59 (10): : 1168 - 1176
  • [46] Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia
    Tzortzis, Vassilios
    Gravas, Stavros
    de la Rosette, Jean J. M. C. H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (06) : 513 - 522
  • [47] Latest Trends and Recommendations on Epidemiology, Diagnosis, and Treatment of Benign Prostatic Hyperplasia (BPH)
    Gabuev, A.
    Oelke, M.
    AKTUELLE UROLOGIE, 2011, 42 (03) : 167 - 178
  • [48] Review of Exercise and the Risk of Benign Prostatic Hyperplasia
    Sea, Jason
    Poon, Kenneth S.
    McVary, Kevin T.
    PHYSICIAN AND SPORTSMEDICINE, 2009, 37 (04) : 82 - 90
  • [49] Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis
    Huang, Shi-Wei
    Tsai, Chung-You
    Tseng, Chi-Shin
    Shih, Ming-Chieh
    Yeh, Yi-Chun
    Chien, Kuo-Liong
    Pu, Yeong-Shiau
    Tu, Yu-Kang
    BMJ-BRITISH MEDICAL JOURNAL, 2019, 367
  • [50] Treatment of benign prostatic hyperplasia: Update and future
    Chiu, Tai-Hua
    Wu, Yi-Hsuan
    Lee, Yung-Chin
    UROLOGICAL SCIENCE, 2023, 34 (02) : 55 - 63